Drug Trial Radar · NCT00627926
A Phase 3 Study of Telaprevir in Combination With Pegasys® and Copegus® in Treatment-Naive Subjects With Genotype 1 Hepatitis C Virus (HCV)
Last checked: Nov 19, 2026Latest source record: Aug 8, 2014 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,095
Actual
Start
Mar 2008
Primary completion
May 2010
Study completion May 2010
Sponsor
- Lead sponsor
- Vertex Pharmaceuticals IncorporatedVertex Pharmaceuticals (VRTX)
- Sponsor type
- Industry
- Collaborators
- Tibotec Pharmaceutical Limited
- First posted
- Mar 4, 2008
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A Phase 3 study to evaluate the efficacy and safety of two dosing regimens of telaprevir in combination with pegylated interferon alfa 2a (Peg-IFN-alfa-2a) and ribavirin (RBV).
Conditions
- Hepatitis C
Interventions
Pegylated Interferon Alfa 2aBiological
subcutaneous injection, 180 micrograms once per week
TelaprevirDrug
375 mg tablets administered orally every 8 hours at a dose of 750 mg
RibavirinDrug
200 mg tablets administered orally twice daily at a dose of 1000 mg/day for subjects weighing \<75 kg and 1200 mg/day for subjects weighing ≥75 kg
PlaceboOther
Telaprevir matching placebo
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Subjects Achieving Sustained Viral Response (SVR), Demonstrated by Achieving Undetectable Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Levels 24 Weeks After Last Planned Dose of Study TreatmentTime frame: 24 weeks after last planned dose of study treatment (up to Week 72)
Locations
116 sites in 13 countries. Site status is shown where the registry gives one.
Site not named
Birmingham, Alabama
Site not named
Birmingham, Alabama
Site not named
Phoenix, Arizona
Site not named
Fresno, California
Site not named
La Jolla, California
Site not named
Long Beach, California
Site not named
Los Angeles, California
Site not named
Los Angeles, California
Site not named
San Diego, California
Site not named
San Diego, California
Site not named
San Diego, California
Site not named
San Francisco, California
Site not named
San Francisco, California
Site not named
San Francisco, California
Site not named
Aurora, Colorado
Site not named
Gainesville, Florida
Site not named
Jacksonville, Florida
Site not named
Jacksonville, Florida
Site not named
Miami, Florida
Site not named
Orlando, Florida
Site not named
Sarasota, Florida
Site not named
South Miami, Florida
Site not named
Atlanta, Georgia
Site not named
Savannah, Georgia
Site not named
Honolulu, Hawaii
Site not named
Chicago, Illinois
Site not named
Carmel, Indiana
Site not named
Indianapolis, Indiana
Site not named
Portland, Maine
Site not named
Baltimore, Maryland
Site not named
Laurel, Maryland
Site not named
Boston, Massachusetts
Site not named
Boston, Massachusetts
Site not named
Worcester, Massachusetts
Site not named
Detroit, Michigan
Site not named
Kansas City, Missouri
Site not named
St Louis, Missouri
Site not named
Omaha, Nebraska
Site not named
Albuquerque, New Mexico
Site not named
Manhasset, New York
Showing 40 of 116 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.